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Background: The goal of the present study was to evaluate the reproducibility of cerebral adenosine A2A receptor
(A2AR) quantification using
11C-TMSX and PET in a test-retest study.
Methods: Five healthy volunteers were studied twice. The test-retest variability was assessed for distribution volume
(VT) and binding potential relative to non-displaceable uptake (BPND) based on either metabolite-corrected arterial
blood sampling or a reference region. The cerebral cortex and centrum semiovale were used as candidate reference
regions.
Results: Test-retest variability of VT was good in all regions (6% to 13%). In the putamen, BPND using the centrum
semiovale displayed a lower test-retest variability (3%) than that of BPND using the cerebral cortex as a reference
region (5%). The noninvasive method showed a higher or similar level of test-retest reproducibility compared to the
invasive method.
Conclusions: Binding reproducibility is sufficient to use 11C-TMSX as a tool to measure the change in A2AR in the
human brain.
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The regional cerebral binding of adenosine A2A recep-
tor (A2AR) antagonists, [7-methyl-
11C]-(E)-8-(3,4,5-
trimethoxystyryl)-1,3,7-trimethylxanthine (11C-TMSX)
[1] and 11C-KW-6002 [2,3], were quantitatively investi-
gated in vivo in healthy human. 11C-TMSX has been
evaluated in human brain studies in not only healthy
human controls [4-7] but also in drug-naïve Parkinson's
disease patients before and after therapy [8]. An aging
effect on A2AR was also evaluated using
11C-TMSX
PET [9]. Several outcome measures, such as distribu-
tion volume (VT), distribution volume ratio (DVR), and
binding potential (BPND), can be used to detect changes
of A2AR binding due to disease progression or thera-
peutic treatment. The reproducibility of these measures
is important to conduct studies to detect change in* Correspondence: mika.naganawa@yale.edu
1PET Center, Yale University School of Medicine, 801 Howard Avenue, PO
Box 208048, New Haven, CT 06520-8048, USA
2Research Team for Neuroimaging, Tokyo Metropolitan Institute of
Gerontology, Tokyo 173-0015, Japan
Full list of author information is available at the end of the article
© 2014 Naganawa et al.; licensee Springer. This
Attribution License (http://creativecommons.or
in any medium, provided the original work is pA2AR. Given that A2AR distribution is heterogeneous,
with only a very small amount of extrastriatal-specific
binding, either the frontal cortex in the rat [3], the
cerebellum in the monkey [10,11], or centrum semio-
vale [7] or cerebral cortex [8,9] in human, was used as
a reference region to estimate non-displaceable binding
of 11C-TMSX. Since only a few postmortem human
brain studies and blocking studies are available, it is not
clear which region is a suitable reference region.
The aim of this paper was to assess the test-retest re-
producibility of PET outcome measures, VT and BPND,
with the centrum semiovale and cerebral cortex as can-
didate reference regions.Methods
Human subjects
All studies were performed under a protocol approved
by the Ethics Committee of the Tokyo Metropolitan In-
stitute of Gerontology. Five healthy, male subjects partic-
ipated in this study (mean age ± SD, 22.4 ± 2.6 years old,
range: 21 to 27 years old). Subjects were all right-handedis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and physical diseases. All subjects did not have a his-
tory of alcoholism and not on any medications to affect
brain function. Caffeine intake was not allowed for at
least 12 h prior to PET scanning. Written informed
consent was obtained from all subjects after receiving
an explanation of the study. Magnetic resonance (MR)
images were acquired on all subjects to eliminate those
with any brain abnormalities and to place regions of
interest (ROIs) on PET images. The MR imaging was
conducted with three-dimensional spoiled gradient-
recalled echo (SPGR) imaging on a SIGNA 1.5 Tesla
machine (General Electric, Waukesha, WI, USA) [6].
Radiochemistry
Radiosynthesis of 11C-TMSX followed the literature pro-
cedure [12]. All procedures were conducted under dim
light to prevent photoisomerization of 11C-TMSX. The
radiochemical purity of 11C-TMSX was >99%.
PET acquisition
Each subject underwent two 11C-TMSX brain PET scans
on two different days, and time of scanning was identical
for test and retest scans of each individual subject, in
order to remove the influence of circadian rhythm. The
inter-scan interval was 28 to 35 days. Dynamic PET im-
ages were acquired in the Positron Medical Center, Tokyo
Metropolitan Institute of Gerontology with the SET-
2400 W PET scanner (Shimadzu, Kyoto, Japan), which ac-
quires 63 slices (3.125-mm slice separation) with a spatial
resolution of 4.4 mm full width at half maximum
(FWHM) and a z-axis resolution of 6.5 mm FWHM [13].
Prior to the scan, a 5-min 68Ga/68Ge transmission scan
was conducted for attenuation correction. 11C-TMSX was
injected intravenously over 60 s. Emission data were col-
lected in two-dimensional mode for 1 h in 27 frames of in-
creasing duration (6 × 10 s; 3 × 30 s; 5 × 1 min; 5 ×
2.5 min; 8 × 5 min). Head movement was minimized with
an air cushion. The dynamic images were reconstructed
by the filtered back-projection method using a Butter-
worth filter (second-order low-pass filter, cutoff frequency
was 1.25 cycles/cm) with corrections for scatter and
randoms.
Input function measurement
In advance of each scan, an arterial catheter was inserted
into the radial artery for blood sampling. After radio-
tracer injection, arterial blood samples were manually
collected every 10 s for the first 2 min and thereafter at
longer intervals, 2.25, 2.5, 3, 5, 7, 10, 15, 20, 30, 40, 50,
and 60 min post-injection. A total of 24 samples were
obtained per scan. Whole blood and plasma were
counted in a cross-calibrated well-type gamma-counter
(BSS-1, Shimadzu, Kyoto, Japan). An additional venousblood sample was taken before 11C-TMSX administra-
tion, which was used for the in vitro assessment of the
fraction of 11C-TMSX in plasma bound to plasma pro-
teins (fP). Arterial blood sampling was not available in
one subject. Thus, a total of five subjects were included
in reference region analyses and four subjects were also
analyzed using plasma data.
Plasma metabolite and protein binding analysis
The fraction of intact radioligand to total plasma activity
was determined from blood samples collected at 3, 10, 20,
30, 40, and 60 min after injection by high-performance li-
quid chromatography (HPLC). The blood was centrifuged
at × 7,000 g for 1 min at 4°C to obtain the plasma, which
was denatured with an equivalent volume of acetonitrile
in an ice-water bath. The suspension was centrifuged
under the same conditions and divided into soluble and
precipitable fractions. The precipitate was resuspended in
2 vol. of 50% aqueous acetonitrile followed by centrifuga-
tion. The recovery yield of the radioactivity in the two sol-
uble fractions was 98.7%. Two soluble fractions were
combined, and into this solution, an equivalent volume of
a solution of 50-mM aqueous acetic acid and 50-mM
aqueous sodium acetate (pH 4.5; 50/50, v/v) was added.
After centrifugation of the samples as described above, the
supernatant was loaded onto a Nova-Pak C8 column
equipped in an RCM 8 × 10 module (8 mm diameter ×
100 mm length; Millipore-Waters, Milford, MA, USA).
The mobile phase was a mixture of acetonitrile, 50-mM
aqueous acetic acid and 50-mM aqueous sodium acetate
(pH 4.5; 4/3/3, v/v/v) at a flow rate of 2 mL/min. The elu-
tion profile was detected with a radioactivity monitor
(FLO-ONE 150TR; Packard Instrument, Meriden, CT,
USA). The retention time of 11C-TMSX was 6.2 min. The
recovery in the eluate of the injected radioactivity was es-
sentially quantitative. The six measured parent fractions
were fitted by a sum of exponential functions. The
metabolite-corrected plasma curve was generated as the
product of the total plasma activity and the fitted parent
fraction curve.
Individual fP values were determined by ultrafiltration.
Prior to administration of 11C-TMSX, approximately
6 mL of blood was taken from each subject. A reference
blood sample was created by adding 22.9 ± 15.7 MBq (at
the time of administration, range: 10.1 to 49.5 MBq of
11C-TMSX in approximately 60 μL to this blood sample
and incubated for 10 min at 37°C). Following centrifuga-
tion (2,000 g at room temperature for 3 min), triplicates of
400 μL aliquots of plasma sample were pipetted into ultra-
filtration tubes (Microcon-30, 30 kDa, Merck Millipore,
Billerica, MA, USA), and centrifuged at room temperature
(14 min at 14,000 g). The free fraction fP was calculated as
the ratio of activity in the ultrafiltrate to the total plasma.
The amount of nonspecific binding of 11C-TMSX to the
Naganawa et al. EJNMMI Research 2014, 4:76 Page 3 of 8
http://www.ejnmmires.com/content/4/1/76filter was also determined by applying the same procedure
to a sample created by addition of 11C-TMSX to saline.
Image analysis
Regions of interest were defined by manually drawing
circles using the registered MR images as additional ref-
erence. The details are written in [6,14]. Time-activity
curves (TACs) were generated for eight ROIs: anterior
putamen, posterior putamen, putamen, caudate head,
thalamus, cerebellum, centrum semiovale, and cerebral
cortex. The putamen ROI consists of the anterior and
posterior putamen subregions. The cerebral cortex ROI
included the frontal, temporal, and occipital cortices.
In the present study, the cerebral cortex and centrum
semiovale were chosen as candidate reference regions.
For 11C-TMSX kinetic analysis, the cerebellum was not
used as a reference region, because A2AR binding in our
previous human study [7] was higher in the cerebellum
than in neocortical regions. In a previous human auto-
radiographic study [15], the density of A2ARs in the
frontal cortex was found to be low, as that in the tem-
poral and occipital cortices.
Outcome measures
The DVR has been used in our previous study on an
aging effect of A2AR in human brain [8,9]. In this study,
the two additional outcome measures, VT and BPND,
were estimated. The definition of the outcome measures
is described in [16]. Regional TACs were analyzed using
the Logan graphical analysis (LGA) with input function
and reference tissue (two-parameter version) [17,18] to
estimate the outcome parameters of VT and BPND. Start-
ing time (t*) was set to 10 min post-injection [7].
Statistical analyses
The test-retest reproducibility was statistically evaluated
according to the following three criteria: signed test-
retest variability (TRV), absolute test-retest variability
(aTRV), and intra-class correlation coefficient (ICC).
TRV was calculated as the difference between the test
and retest measurements, divided by the mean of the
test and retest values (2 × (ptest − pretest)/(ptest + pretest)).
aTRV was calculated as the absolute value of TRV (2 × |
ptest − pretest|/(ptest + pretest)). TRV indicates whether
there is a systematic trend between the test and retest
scans. The test-retest reliability of the two parameter
measurements was the ICC calculated using the follow-
ing equation [19]:
ICC ¼ BSMSS − WSMSS
BSMSS þ WSMSS
where BSMSS and WSMSS are the mean sum of squares
between subjects and within subjects, respectively. Inthe test-retest study, an ICC value ranges from −1 (no
reliability) to 1 (maximum reliability) [20,21]. Sample
sizes were calculated to detect a 20-percent difference in
BPND between independent groups (two-tails t-test)
using the software G*power 3.1 [22]. The confidence
level was set to be 5% (P < 0.05) and statistical power to
0.8. The mean of the test scans was used as the mean of
baseline scans, and the SDs of the baseline and blocking
scans were assumed to be same as the SDs of the test
scans. All statistical parameters except for power analysis
were calculated with MATLAB Version 7.12.0.635 (the
MathWorks Inc., Natick, MA, USA) and Microsoft Excel
2010 (Microsoft, Redmond, WA, USA).
Results
Injection parameters
Mean injected radioactivity and mean specific activity at
the time of injection were 687 ± 73 MBq (range: 615 to
767 MBq) and 195 ± 80 GBq μmol−1 (range: 131 to
305 GBq μmol−1), respectively, for test scans (n = 5) and
731 ± 53 MBq (range: 690 to 822 MBq, n = 5) and 143 ±
60 GBq μmol−1 (range: 87 to 213 GBq μmol−1), respect-
ively, for retest scans (n = 5). The injected dose and spe-
cific activity did not significantly differ between the test
and retest scans (paired t-test, P = 0.21 for injected dose
and P = 0.24 for specific activity).
Arterial input function
Figure 1A shows the averaged radioactivity in plasma with
metabolite correction for test and retest scans (n = 4). The
metabolism speed of 11C-TMSX was slow in both scans
(Figure 1B): the unchanged fraction was still 85% ± 5% in
test scan and 82% ± 6% in retest scan at 60 min post-
injection. The free fraction of 11C-TMSX in plasma was
2.40% ± 0.96% for test scans and 2.40% ± 0.47% for retest
scans. There are no significant differences in fP between
test and retest scans (paired t-test, P = 0.72). The
ultrafiltrate-to-saline ratio was 46% ± 3% in test scans
and 46% ± 3% in retest scan, indicating a high retention
on the filter.
Quantitative analysis
Brain activity in all regions reached the peak around
5 min post-injection of 11C-TMSX, and then gradually
decreased. The average tissue-to-plasma ratio was shown
in Figure 2. Typical parametric images of BPND were dis-
played in Figure 3 using a centrum semiovale as a refer-
ence region. The ratios in most regions became constant
around 20 min post-injection of 11C-TMSX. The ratios
in the putamen were decreased slightly throughout the
scan. The values for VT and BPND were summarized in
Tables 1, 2, and 3. For each outcome parameter, the
mean of the test and retest scans, the TRV (mean ±
standard deviation), the aTRV, and the ICC were listed.
Figure 1 Mean ± SD of metabolite-corrected input function and unmetabolized11C-TMSX fraction. (A) Mean ± SD of metabolite-corrected
input function for four healthy human subjects. The inserted graph corresponds to early data. The unit of plasma data was SUV [concentration/
(injected dose/body weight)]. (B) Mean ± SD of unmetabolized 11C-TMSX fraction and mean of fitted curve for four healthy human subjects. The
parent fraction was fitted using a sum of exponentials. Open and closed circles correspond to test and retest scans, respectively. Error bars show
the standard deviation.
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ways smaller than its standard deviation, indicating that
there is no systematic trend between test and retest scans.
The absolute TRV was ≤10% except for the thalamus. The
ICC values were moderate (>0.65) except for the thalamus
(0.27). We also calculated the normalized VT (VT/fP). Glo-
bal mean aTRV values were 8% and 15% for VT and VT/fP,
respectively, indicating that normalizing by the plasma
free fraction fp increased the variability of the outcome
measure for 11C-TMSX. For BPND values, the mean TRV
was between ±10% using either cerebral cortex or cen-
trum semiovale as a reference region, and always smaller
than its standard deviation, further indicating that there
was no systematic trend between test and retest scans.
Since BPND of the cerebellum from one subject was close
to 0 in the test and retest scans with reference LGA with
the cerebral cortex as a reference region, TRVs of the sub-
ject were different from the other subjects. Those values
were removed from Table 2.
The mean BPND values were larger, and the TRV and
aTRV were smaller when using the centrum semiovale
as reference instead of the cerebral cortex. Global meanFigure 2 Tissue-to-plasma ratio curve averaged across subjects (n = 4
and cortex (circles) and (B) caudate head (diamonds), thalamus (triangles),
show test and retest scans, respectively. Error bars show the standard deviaaTRV values were 8% and 15% for BPND using the cen-
trum semiovale and cerebral cortex, respectively, as a
reference region. Both TRVs using LGA with input func-
tion were comparable to those values using reference
LGA. The BPND estimates using LGA with input func-
tion were in excellent agreement with those from refer-
ence LGA (BPND, reference LGA = 1.00 BPND, LGA + 0.01,
R2 = 1.00 with the cerebral cortex as a reference region,
BPND, reference LGA = 1.05 BPND, LGA + 0.01, R
2 = 0.98 with
the centrum semiovale).
Power analysis (two-tails t-test, statistical power 0.8) was
conducted to estimate the samples sizes to detect a 20-
percent difference in BPND. Using the cerebral cortex as a
reference region, sample sizes ranged from 4 (thalamus)
to 21 (caudate head) per group. Using the centrum semio-
vale as a reference region reduced the required sample
sizes: 3 (putamen and thalamus) to 9 (caudate head).
Discussion
The plasma free fraction (fP) was measured in this study,
allowing for correction of VT values. This correction by
fP is useful if fP can be measured reliably and if there is) in six ROIs. ROIs are (A) putamen (diamonds), cerebellum (triangles),
and centrum semiovale (squares). Open symbols and closed symbols
tion.
Figure 3 Typical example of parametric image for BPNDin (A) test and (B) retest conditions. The centrum semiovale was used as a reference
region. The parametric image was fused with the individual subject’s MR image.
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the fP was consistently low (<3%), with evidence that
11C-TMSX stuck to the ultrafiltration tubes, which may
lead to underestimation of fp. However, the fP value mea-
sured in [23] was 9.1% ± 0.4% (n = 6, human) by the
ultrafiltration method. Such a discrepancy might be at-
tributable to high stick factor in our data. Note that the
stick factor was not reported in [23]. Another possibil-
ity is the difference in the preparation of the injection
solution. Finally, the signed and absolute TRVs were
larger for VT/fP compared to those of VT. Hence, the
normalization of VT by fP did not reduce variability in
this case.
Inter-subject variability (% coefficient of variation
(COV)) of VT at retest scans were lower (approximately
7%) than that of the test scans (approximately 16%),









Putamen 1.43 (15%) 1.40 (6%) 8 1.0 ± 10 0.69
Anterior putamen 1.46 (15%) 1.44 (7%) 7 0.8 ± 10 0.68
Posterior putamen 1.39 (16%) 1.37 (6%) 10 1.2 ± 11 0.66
Caudate head 1.33 (15%) 1.26 (9%) 6 4.4 ± 7 0.77
Thalamus 1.30 (17%) 1.23 (2%) 13 4.4 ± 16 0.27
Cerebellum 1.20 (15%) 1.16 (8%) 7 2.6 ± 8 0.77
Cerebral cortex 0.98 (18%) 0.94 (9%) 7 2.8 ± 10 0.74
Centrum semiovale 0.71 (16%) 0.70 (7%) 7 0.6 ± 10 0.73
aLogan graphical analysis with input function (t* = 10 min) (n = 4). Data are
presented as mean (%COV); bTRV = (ptest − pretest)/(ptest + pretest) × 2, and aTRV is
the absolute value of TRV; cICC = (BSMSS −WSMSS)/(BSMSS +WSMSS) where
BSMSS is the mean sum of squares between subjects and WSMSS is the mean
sum of squares within subjects.injected dose, specific activity, and fP of
11C-TMSX. An-
other possibility to explain the difference in the inter-
subject variability is a difference in the metabolism of
the tracer. The subjects were controlled for caffeine in-
take, but not for smoking habituations. Nicotine con-
sumption might change the metabolism of 11C-TMSX
as seen in the study with adenosine A1 receptor ligand
18 F-CPFPX [24]. In a retrospective investigation, it
turned out that subjects consisted of a nonsmoker, a
smoker (blood sampling was not available), and three
subjects with unknown status. However, the parent
fraction of 11C-TMSX was very high and well reproducible
(Figure 1B). Therefore, we concluded that a change in the
metabolism speed was not a reason to increase the inter-
subject variability. In contrast to VT, such a difference in
the inter-subject variability did not exist in BPND. The
difference in the %COV between test and retest scans
might come from errors included in the input function
measurement.
The test-retest variability and reliability of VT were
good (aTRV ≤10%, ICC >0.6) across regions except for
the thalamus (aTRV: 13% and ICC: 0.27). For BPND, a
good absolute TRV was seen in the high A2A regions
(putamen and caudate). However, lower-binding regions
(BPND < 0.4) showed high aTRV (>15%) and low ICC
values; this is not surprising, since BPND is small in
those regions. We examined the test-retest variability
data of VT and BPND from a number of radioligands.
The aTRV of VT of
11C-TMSX (8% averaged across all
regions) was comparable to that of other radioligands
used to study dopamine and adenosine receptors. The
reported aTRV values of VT were 5% to 11% (average:
7%) with 11C-FLB457 [25] for dopamine D2/3 receptor
and 12% to 14% (average: 13%) with 18 F-CPFPX [26] for
Table 2 Test-retest variability and reproducibility of binding potential (BPND) using cerebral cortex as a reference
region
Regions
Logan graphical analysis with input function (t* = 10 min, n = 4) Reference Logan graphical analysis (t* = 10 min, n = 5)
Testa Retesta aTRVb [%] TRVb[%] ICCc Testa Retesta aTRVb [%] TRVb [%] ICCc
Putamen 0.46 (11%) 0.49 (9%) 6 −6 ± 5 0.77 0.50 (17%) 0.53 (16%) 5 −5 ± 4 0.94
Anterior putamen 0.50 (15%) 0.52 (6%) 11 −6 ± 11 0.48 0.53 (18%) 0.57 (16%) 11 −7 ± 9 0.80
Posterior putamen 0.42 (15%) 0.45 (13%) 14 −6 ± 15 0.47 0.47 (21%) 0.48 (16%) 11 −2 ± 13 0.80
Caudate head 0.37 (23%) 0.33 (13%) 21 8 ± 26 0.18 0.38 (20%) 0.39 (29%) 19 0 ± 24 0.58
Thalamus 0.33 (8%) 0.31 (34%) 25 9 ± 31 0.38 0.33 (8%) 0.32 (27%) 22 5 ± 28 0.24
Cerebellum 0.23 (20%) 0.23 (14%) 15 −1 ± 22 0.44 0.23 (20%)d 0.23 (14%)d 14d −2 ± 22d 0.47d
aData are presented as mean (%COV); bTRV = (ptest − pretest)/(ptest + pretest) × 2, and aTRV is the absolute value of TRV;
cICC = (BSMSS −WSMSS)/(BSMSS +WSMSS)
where BSMSS is the mean sum of squares between subjects and WSMSS is the mean sum of squares within subjects; dValues for the cerebellum were calculated
from four subjects.
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11C-
TMSX was comparable to that with 11C-FLB457 (6% to
15%) and larger than that with 18 F-FPFPX (3% to 9%).
Given the good reproducibility of VT,
11C-TMSX should
be suitable for use in receptor occupancy studies with in-
put function. The range of VT values was not wide across
regions (0.70 to 1.46 mL/cm3). However, using the occu-
pancy plot [27] is feasible using the regions with a narrow
range of VT values with
11C-GSK931145 for glycine type 1
transporter (0.43 to 0.79 mL/cm3) [28] and 18 F-CPFPX
for adenosine A1 receptor (0.42 to 0.82 mL/cm
3) [29].
Note that the occupancy plot assumes that the receptor
occupancies are uniform in all regions of interest. Previous
reports [1,30] suggest that some regions might have an
‘atypical’ binding. Therefore, we need to carefully choose
regions used for the occupancy plot with 11C-TMSX. An-
other possible way for estimating receptor occupancy is to
estimate a relationship between blocking dose (or plasma
level) and VT for each region [31]. This second method
can be used even if all regions have the same baseline VT.
The test-retest variability of BPND values using the
cerebral cortex as a reference region was larger than
those using the centrum semiovale. In the striatum, the
high A2AR-binding region, the aTRVs of BPND were 5%
in the putamen and 19% in the caudate head using theTable 3 Test-retest variability and reproducibility of binding
region
Regions Logan graphical analysis with input function (t* = 10
Testa Retesta aTRVb [%] TRVb [%]
Putamen 1.02 (6%) 1.01 (4%) 1 1 ± 2
Anterior putamen 1.07 (4%) 1.06 (3%) 4 1 ± 6
Posterior putamen 0.97 (12%) 0.96 (7%) 6 1 ± 10
Caudate head 0.89 (14%) 0.80 (5%) 13 10 ± 14
Thalamus 0.84 (6%) 0.77 (14%) 14 9 ± 17
Cerebellum 0.70 (9%) 0.65 (2%) 8 6 ± 9
aData are presented as mean (%COV); bTRV = (ptest − pretest)/(ptest + pretest) × 2, and aT
where BSMSS is the mean sum of squares between subjects and WSMSS is the meacerebral cortex as a reference region. On the other hand,
the aTRVs of BPND were 3% in the putamen and 13% in
the caudate head using the centrum semiovale as a refer-
ence region. This is partly because the BPND value was
smaller using the cerebral cortex as a reference region.
The thalamus showed a low reproducibility of both VT
and BPND values. Moreover, while the mean distribution
volume in the thalamus was high, a postmortem study
with 3H-SCH58261 [15] showed that A2AR density is low.
The uptake in the thalamus is considered to be ‘atypical’
binding [1,30], which is different from classical A2AR
binding. This low reproducibility in the thalamus may be
partly due to such an ‘atypical’ binding. Thus, given the
low reproducibility and ‘atypical’ binding, the thalamus
should be carefully considered in further clinical research.
Using either the cerebral cortex or centrum semiovale
as a reference region, reference LGA and LGA with in-
put function provided similar BPND values. The TRV
and aTRV of BPND were slightly smaller using the refer-
ence LGA. Not surprisingly, the reference tissue model
is not affected by errors in the measurement of input
function. This suggests that the reference LGA can be
useful for further studies.
There are two limitations of this study: unknown opti-
mal reference region for 11C-TMSX and small samplepotential (BPND) using centrum semiovale as a reference
min, n = 4) Reference Logan graphical analysis (t* = 10 min, n = 5)
ICCc Testa Retesta aTRVb [%] TRVb [%] ICCc
0.90 1.06 (9%) 1.03 (7%) 3 2 ± 4 0.87
−0.10 1.10 (9%) 1.09 (4%) 5 1 ± 6 0.69
0.53 1.02 (12%) 0.97 (11%) 7 5 ± 8 0.68
0.00 0.90 (17%) 0.85 (2%) 13 4 ± 17 0.11
−0.37 0.83 (22%) 0.77 (19%) 15 7 ± 17 0.65
0.05 0.63 (42%) 0.58 (41%) 10 8 ± 9 0.95
RV is the absolute value of TRV; cICC = (BSMSS −WSMSS)/(BSMSS +WSMSS)
n sum of squares within subjects.
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study using an antagonist radiotracer in vivo in human
brain is a 11C-KW-6002 PET study with varying dose of
cold KW-6002 [3] However, blocking results in the cen-
trum semiovale and neocortical regions were not in-
cluded in the report. Thus, the suitability of the cerebral
cortex or central semiovale as a reference region has yet
to be determined by blocking or occupancy studies. Due
to a lack of blocking study and postmortem study in the
regions with low A2AR density, the region with lowest
VT was chosen. For the SPECT A2AR tracer
123I-MNI-
420, while a reference region is not yet validated, a test-
retest reproducibility of BPND was evaluated to facilitate
the comparison between 123I-MNI-420 and other A2AR
radiotracers [32]. We also took an exploratory approach
to calculate BPND values using candidate reference re-
gions in order to evaluate BPND reproducibility. How-
ever, the determination of the reference region is most
desirable in order to establish the utility of 11C-TMSX
for PET imaging. In this study, we evaluated outcome
measures with input function in four subjects. We exam-
ined sample sizes for test-retest human studies using other
radioligands. As far as we know, the minimum sample size
is three subjects for test-retest protocol (18 F-MK-6577
[33] for glycine transporter type 1 and 123I-MNI-420 [32]
for A2AR).
Conclusions
The quantification of 11C-TMSX imaging was reprodu-
cible for PET studies of A2AR. The LGA with input func-
tion achieved good reproducibility for VT in all regions.
The results support the use of PET and 11C-TMSX as a
suitable tool for receptor occupancy studies. The use of
the cerebral cortex or centrum semiovale as a reference
region with invasive and reference LGA produced good
or moderate reproducibility of the BPND in high A2AR
regions. While the centrum semiovale showed higher re-
producibility of the BPND, blocking studies are required
to determine the optimal reference region conclusively.
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